OTC Medicines: Development and Licensing
Diapharm provides portfolio consulting and supports clients in refining their portfolio strategy, with a particular focus on phytopharmaceuticals.
Authorizations and licenses
By acquiring existing OTC licenses, approved OTC registrations, or ready-to-submit OTC dossiers, pharmaceutical companies can move quickly to market. Once the decision is made for a specific indication or active ingredient, Diapharm researches which registrations and products are in development or immediately available on the market. Whether through in-licensing, co-marketing, or outright purchase, Diapharm identifies product options and facilitates the transfer of existing registrations.
Targeted Registration Searches
Targeted searches for available registrations and dossiers are a critical success factor for clients wishing to bring a new product to market without the lengthy process of developing it from scratch. Diapharm conducts Europe-wide screening in multiple databases to identify available registrations, evaluates the options, and provides clients with tailored overviews that include clear strategic recommendations and prioritizations. Diapharm supports the entire process, from initial outreach and feasibility checks to full business development activities.
Next-Generation OTC Products
More and more people are taking responsibility for their own health. OTC medicines, medical devices, and dietary supplements make a significant contribution to preventive healthcare and well-being—while also helping to reduce rising costs within the professional healthcare system.
Diapharm supports clients throughout the entire journey — from formula development and identifying suitable contract manufacturers to regulatory communications and market launch.
Development of new OTC medicines
Diapharm develops herbal medicines for the pharmaceutical industry, focusing primarily on OTC products, but also Rx medicines. The process begins with the screening of suitable active ingredients and continues through to full regulatory approval. This results in new products and licensing opportunities that help pharmaceutical companies strategically expand and strengthen their portfolios — either on behalf of clients or through Diapharm’s own in-house developments.
